Aquestive Therapeutics, Inc. today announced the completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (“FDA”) for AQST-109 (epinephrine sublingual film) for the treatment of severe allergic reactions includ...
Patients were excluded from the trial if they had evidence of lymph node (N2-N3) or metastatic (M1) disease at screening; received prior pelvic radiotherapy within 2 years of randomization; or had previous exposure to immune-mediated therapies (excluding Bacillus Calmette-Guérin). Current or prio...
Lilly Signs Back-to-Back Deals in MASH, Cancer February 11, 2025 · 2 min read · Tristan Manalac Pain Vertex Eyes Expansive, Easy Access for Journavx in Coming Weeks February 11, 2025 · 2 min read · Tristan Manalac Mergers & acquisitions ...
The Company plans to meet with the FDA in early 2023 to discuss potential future clinical trial requirements with the goal of being in position to initiate a Phase 2/3 clinical trial for the treatment of wet AMD as early as Q3 2023, subject to obtaining additional funding for the ...
Moreover, grid-connected fast charging can cause sudden load peaks, hamper generation- demand balance, cause voltage flickers and phase fluctuations, deteriorate power quality, and induce current harmonics and supra-harmonics. Due to aging infrastructure and integration of variable PV and wind sources,...